It’s only fair to share… Islatravir (MK-8591, EFdA) 2′-Deoxy-4′-ethynyl-2-fluoroadenosine Molecular FormulaC12H12FN5O3 Average mass293.254 Da 865363-93-5 2′-Deoxy-4′-ethynyl-2-fluoroadenosine 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Adenosine, 2′-deoxy-4′-C-ethynyl-2-fluoro- (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol 2′-deoxy-4′-c-ethynyl-2-fluoroadenosine 865363-93-5 [RN] 9H-Purin-6-amine, 9-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)-2-fluoro- E2FDA (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol MK-8591 UNII:QPQ082R25D Islatravir is known to be a nucleoside reverse transcriptase inhibitor, useful for treating HIV-1 and -2 infection and AIDS. Islatravir (MK-8591, EFdA), useful for the treatment of …
LNS-8801 (SRR G-1)
It’s only fair to share… LNS-8801 (SRR G-1) CAS 925419-53-0 Chemokine receptor-like 2 agonist C21 H18 Br N O3, 412.28 Ethanone, 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- 1-((3aS,4R,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one 1-[(3aS,4R,9bR)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone G 1 G 1 (estrogen receptor agonist) Linnaeus Therapeutics Inc NOTE 1-((3aR,4S,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one (RSS G-1 or LNS8812) Novel crystalline forms of an enantiomerically purified LNS-8801 (SRR G-1), or a derivative useful for treating cancer, …
CC-90010
It’s only fair to share… CC-90010 C21 H21 N O4 S, 383.46 CAS 1706738-98-8 1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- 4-[2-(Cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl-1(2H)-isoquinolinone 4-[2-(Cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one 4-[2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Quanticel Pharmaceuticals Inc, Michael John BennettJuan Manuel BetancortAmogh BoloorStephen W. KaldorJeffrey Alan StaffordJames Marvin Veal Celgene (now a wholly owned subsidiary of Bristol-Myers Squibb ) , following its acquisition of Quanticel , is developing CC-90010, an oral inhibitor of BET (bromodomain and extraterminal) …
Delgocitinib
It’s only fair to share… Delgocitinib デルゴシチニブ 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)- 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile Formula C16H18N6O CAS 1263774-59-9 Mol weight 310.3537 Approved, Japan 2020, Corectim, 2020/1/23, atopic dermatitis, Japan Tobacco (JT) Torii 7/23/2025 fda approved, Anzupgo To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response UNII-9L0Q8KK220, JTE-052, LP-0133, ROH-201, 9L0Q8KK220, LEO 124249A, LEO 124249, HY-109053 CS-0031558, D11046, GTPL9619, JTE-052A, JTE052 Delgocitinib, also known as …
Dotinurad ドチヌラド
It’s only fair to share… Dotinurad ドチヌラド (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone Formula C14H9Cl2NO4S CAS 1285572-51-1 Mol weight 358.1966 PMDA, Urece, APROVED JAPAN 2020/1/23, Antihyperuricemic 305EB53128UNII-305EB53128 1285572-51-1, VOFLAIHEELWYGO-UHFFFAOYSA-N HY-109031 CS-0030545 Dotinurad is a urate transporter inhibitor. Patents WO 2011040449 https://patents.google.com/patent/WO2011040449A1/en Uric acid is produced by metabolizing a purine produced by the degradation of a nucleic acid in the body and adenosine …
IIIM-290
It’s only fair to share… IIIM-290 4H-1-Benzopyran-4-one, 2-[2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]- Molecular Weight 462.32 Formula C₂₃H₂₁Cl₂NO₅ CAS No. 2213468-64-3 CSIR-IIIM Jammu has filed an IND Application of “IIIM-290” to Drug Controller General of India for conducting Phase I/Phase II clinical trial of its capsule formulation in patients with locally advanced or metastatic pancreatic cancer. This IND candidate …
Zanubrutinib, ザヌブルチニブ , занубрутиниб , زانوبروتينيب ,
It’s only fair to share… Zanubrutinib, BGB-3111 Formula C27H29N5O3 CAS 1691249-45-2 Mol weight 471.5509 FDA , 2019/11/14, Brukinsa ザヌブルチニブ , занубрутиниб [Russian] زانوبروتينيب [Arabic] (7S)-7-(1-Acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-, (7S)- Antineoplastic, Bruton’s tyrosine kinase inhibitor, Mantle cell lymphoma Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[3] …
Teprotumumab-trbw
It’s only fair to share… Tepezza (teprotumumab-trbw) Company: Horizon Therapeutics plc Date of Approval: January 21, 2020 Treatment for: Thyroid Eye Disease Labels for BLA 761143 UNIIY64GQ0KC0A CAS number1036734-93-6 R-1507 / R1507 / RG-1507 / RG1507 / RO-4858696 / RO-4858696-000 / RO-4858696000 / RO4858696 / RO4858696-000 / RV-001 / RV001 Tepezza (teprotumumab-trbw) is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) for the treatment of active thyroid eye …
ENCORAFENIB, エンコラフェニブ
It’s only fair to share… ENCORAFENIB, エンコラフェニブ UNII:8L7891MRB6 Formula:C22H27ClFN7O4S, Average: 540.01 1269440-17-6 BRAFTOVI NVP-LGX818 NVP-LGX-818-NXA NVP-LGX818-NXA ENCORAFENIB [USAN] ENCORAFENIB [WHO-DD] ENCORAFENIB ENCORAFENIB [INN] METHYL N-((2S)-1-((4-(3-(5-CHLORO-2-FLUORO-3-(METHANESULFONAMIDO)PHENYL)(-1-(PROPAN-2-YL)-1H-PYRAZOL-4-YL(PYRIMIDIN-2-YL)AMINO)PROPAN-2-YL)CARBAMATE CARBAMIC ACID, N-((1S)-2-((4-(3-(5-CHLORO-2-FLUORO-3-((METHYLSULFONYL)AMINO)PHENYL)-1-(1-METHYLETHYL)-1H-PYRAZOL-4-YL)-2-PYRIMIDINYL)AMINO)-1-METHYLETHYL)-, METHYL ESTER LGX818 LGX-818 Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic …
GRAPIPRANT
It’s only fair to share… GRAPIPRANT Molecular FormulaC26H29N5O3S Average mass491.605 Da CAS 415903-37-6 UNII-J9F5ZPH7NB, CJ 023423, CJ-023423, Phase II, Arrys Therapeutics, CANCER, PAIN, AskAt Phase II, N-{2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}-N’-[(4-methylphenyl)sulfonyl]urea RQ-00000007, MR10A7 9763 AAT-007 Benzenesulfonamide, N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl- CJ-023,423 N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 1-[2-[4-(2-Ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea 2-Ethyl-4,6-dimethyl-1-[4-[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]-1H-imidazo[4,5-c]pyridine AAT 007 CJ 023423 Grapiprant MR 10A7 RQ 00000007 RQ 7 Synonyms and Mappings 415903-37-6 GRAPIPRANT [GREEN BOOK] CJ-023 GRAPIPRANT [INN] GRAPIPRANT [WHO-DD] MR-10A7 …